Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479024
Status:
COMPLETED
Last Update Posted:
2009-09-30
First Post:
2007-05-23
Brief Title:
Follow-up Study to Previous CARE Trial
Sponsor:
Bracco Diagnostics Inc
Organization:
Bracco Diagnostics Inc
Study Overview
Official Title:
CARE Visipaque 320 and Isovue 370 in Cardiac Angiography in REnally Impaired Patients FOLLOW-UP STUDY
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue-370 or Visipaque 320 as part of the IOP-104 trial protocol and were evaluable for determination of post-contrast significant renal injury defined as 25 increase in SCr or 25 increase in cystatin C
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None